Cassava Sciences announced the DOJ closed its probe into research misconduct allegations, concluding investigations by both the DOJ and SEC. The company is now pivoting to develop Simufilam for TSC-related epilepsy. Despite the legal resolution, shares traded 2% lower as the company moves forward with its new focus.